For the current week, the overall ratings of 10 biotechnology stocks are worse, according to the Portfolio Graderdatabase. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
This week, CEL-SCI Corporation (CVM) falls to a D (“sell”), worse than last week’s grade of C (“hold”). CEL-SCI is developing new immune system based treatments for cancer and infectious diseases. In Portfolio Grader’s specific subcategories of Equity and Cash Flow, CVM also gets F’s. To get an in-depth look at CVM, get Portfolio Grader’s complete analysis of CVM stock.
This week, EPIRUS Biopharmaceuticals, Inc.’s (EPRS) rating worsens to a D from the company’s C rating a week ago. The stock also gets an F in Earnings Revisions. For more information, get Portfolio Grader’s complete analysis of EPRS stock.
The rating of Ohr Pharmaceutical Inc (OHRP) declines this week from a C to a D. Ohr Pharmaceutical develops pharmaceuticals for wound care and to treat cachexia. The stock gets F’s in Earnings Revisions and Equity. Trade volume dipped significantly in the past week, slipping to half of the previous rate. To get an in-depth look at OHRP, get Portfolio Grader’s complete analysis of OHRP stock.
Trius Therapeutics, Inc. (TSRX) earns a D this week, falling from last week’s grade of C. Trius Therapeutics is a biopharmaceutical company. The stock receives F’s in Earnings Growth, Earnings Momentum and Equity. Cash Flow and Sales Growth also get F’s. For more information, get Portfolio Grader’s complete analysis of TSRX stock.
Slipping from a C to a D rating, Vical Incorporated (VICL) takes a hit this week. Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The stock gets F’s in Equity and Cash Flow. To get an in-depth look at VICL, get Portfolio Grader’s complete analysis of VICL stock.
Synergy Pharmaceuticals, Inc. (SGYP) earns an F (“strong sell”) this week, moving down from last week’s grade of D (“sell”). Synergy Pharmaceuticals is a biopharmaceutical company focused on the development of drugs to treat gastrointestinal disorders and diseases. The stock gets F’s in Equity and Cash Flow. As of July 22, 2015, 20.5% of outstanding Synergy Pharmaceuticals, Inc. shares were held short. For more information, get Portfolio Grader’s complete analysis of SGYP stock.
Verastem, Inc. (VSTM) is having a tough week. The company’s rating falls from a D to an F. Verastem is a biopharmaceutical company which is focused on discovering and developing novel drugs that selectively target cancer stem cells in breast and other cancers along with proprietary companion diagnostics. The stock gets F’s in Equity and Cash Flow. As of July 22, 2015, 11.6% of outstanding Verastem, Inc. shares were held short. To get an in-depth look at VSTM, get Portfolio Grader’s complete analysis of VSTM stock.
The rating of Celldex Therapeutics, Inc. (CLDX) declines this week from a C to a D. Celldex Therapeutics is engaged in the discovery, development and commercialization of products that harness the human immune system to prevent and treat disease. The stock also gets an F in Equity. As of July 22, 2015, 16.7% of outstanding Celldex Therapeutics, Inc. shares were held short. For more information, get Portfolio Grader’s complete analysis of CLDX stock.
This is a rough week for Trevena, Inc. (TRVN). The company’s rating falls to D from the previous week’s C. The stock gets F’s in Equity and Cash Flow. To get an in-depth look at TRVN, get Portfolio Grader’s complete analysis of TRVN stock.
Vital Therapies, Inc. (VTL) gets weaker ratings this week as last week’s C drops to a D. The stock gets F’s in Equity and Cash Flow. For more information, get Portfolio Grader’s complete analysis of VTL stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
